Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (clinicaltrials.gov) - P3 | N=458 | Not yet recruiting | Sponsor: Weifang Medical University

New P3 trial • Cardiovascular • CNS Disorders • Ischemic stroke

Post-Thrombolysis Antiplatelet Strategies and Functional Recovery in Mild Ischemic Stroke with Disabling Symptoms: A Retrospective Cohort Study. (PubMed, Neurol India) - "Tirofiban bridging followed by dual antiplatelet therapy may enhance early neurological recovery and long-term functional outcomes without increasing bleeding risk in MIS patients with disabling symptoms or END."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Stroke. (PubMed, CNS Drugs) - "Nevertheless, a recent randomized controlled trial encouragingly demonstrated that ultra-early intravenous administration of the antiplatelet agent tirofiban after IVT was effective at improving functional outcomes in non-cardioembolic stroke patients with a low risk of hemorrhage. However, the considerable heterogeneity in both antithrombotic regimens and patient populations across existing studies has obscured the identification of beneficial candidates and intervention protocols for early post-thrombolysis antithrombotic therapy. We synthesizes the current evidence regarding patient selection, drug choice, and optimal timing for early antithrombotic therapy, to explore potential improvements in post-IVT antithrombotic management, emphasizing the critical need to balance the prevention of ischemic progression with the risk of hemorrhagic transformation."

Journal • Review • Cardiovascular • Hematological Disorders • Ischemic stroke

Improving Neuroprotective Strategy for Ischemic Stroke before Endovascular Thrombectomy by Intravenous Tirofiban (ChiCTR) - P3 | N=884 | Not yet recruiting | Sponsor: General Hospital of Northern Theater Command; General Hospital of Northern Theater Command

New P3 trial • Cardiovascular • Ischemic stroke

A study on the safety and efficacy of tirofiban in elderly patients with acute cerebral infarction (ChiCTR) - P4 | N=360 | Recruiting | Sponsor: Hengzhou People’s Hospital; Hengzhou People’s Hospital

New P4 trial • Cardiovascular • CNS Disorders • Ischemic stroke

Trialist: Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial (ISC 2026) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular

Evaluation of the Satety Profile of the Tirofiban Protocol for Select Patients with Acute Ischemic Stroke at a United States Comprehensive Stroke Center (ISC 2026) - "In the recent RESCUE BT2 trial in China, intravenous (IV) tirofiban in patients without medium or large vessel occlusions was associated with an improvement in functional outcomes compared to aspirin monotherapy, though with slightly higher incidence of intracranial hemorrhage. The median mRS at 90 days was 3.Conclusion This study demonstrated that IV tirofiban has a favorable safety profile in patients with recent onset or progression of stroke symptoms and non-occluded medium and large-sized cerebral vessels. We plan to compare it to dual-antiplatelet therapy in the future."

Clinical • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Ischemic stroke • Thrombocytopenia

Efficacy and safety of early tirofiban administration after Intravenous thrombolysis in patients with acute ischemic stroke: The multicenter, randomized, double-blind, placebo-controlled RESCUE BT3 trial (ISC 2026) - "Available on Wednesday, February 04, 2026 at 08:00am CST."

Clinical • Cardiovascular • Ischemic stroke

Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial (ISC 2026) - "Available on Thursday, February 05, 2026 at 12:15pm CST."

Clinical • Late-breaking abstract • Cardiovascular

Adjunct Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke: A Systemic Review and Meta-analysis of Randomized Trials (ISC 2026) - "Across randomized trials, adjunct tirofiban after IVT improved ninety-day functional outcomes without a detectable increase in hemorrhage or death. Larger, multicenter trials are warranted to refine timing, dosing, and selection of candidates."

Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Primary angioplasty/stenting versus mechanical thrombectomy as the initial approach for underlying ICAD-LVO: a multicenter retrospective cohort study. (PubMed, Front Neurol) - "Among 161 included patients (94 AS vs. 67 MT), baseline characteristics were balanced except for a higher prevalence of hyperlipidemia (p = 0.041), progressive stroke (p < 0.001), and tirofiban administration (p = 0.043) in the AS group...This approach showed higher rates of 90-day functional independence while maintaining a comparable safety profile. These findings support the concept of etiology-specific endovascular strategies; however, this approach requires confirmation in prospective randomized controlled trials."

Journal • Retrospective data • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Dyslipidemia • Hematological Disorders

Association Between the Aggregate Index of Systemic Inflammation (AISI) and Tirofiban Use During Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction. (PubMed, Medicina (Kaunas)) - " Elevated AISI was independently associated with tirofiban use during primary PCI, indicating that systemic inflammatory status parallels intraprocedural decision-making in STEMI. Although its discriminative performance was modest, AISI reflects systemic inflammatory-thrombotic activation in this clinical setting."

Journal • Cardiovascular • Hematological Disorders • Inflammation • Myocardial Infarction • Thrombosis

COMPARISON OF TIROFIBAN VERSUS CANGRELOR AS A TEMPORARY ANTIPLATELET BRIDGING AGENT FOR CORONARY STENT PROTECTION (ACC 2026) - "Abstract is embargoed at this time."

ATTRACTION: Tirofiban After Successful MT Recanalization in AIS (clinicaltrials.gov) - P2/3 | N=1380 | Completed | Sponsor: Xiang Luo | Recruiting ➔ Completed

Trial completion • Cardiovascular • Ischemic stroke

Development and validation of a clinical model for predicting 90-day outcomes after endovascular therapy with adjunctive tirofiban in acute ischemic stroke. (PubMed, Front Neurol) - "We developed and validated a pragmatic prediction model incorporating readily available clinical and procedural variables to estimate the risk of 90-day poor outcome in AIS-LVO patients treated with EVT and tirofiban. This tool may assist clinicians in individualized outcome prediction and inform adjunctive antithrombotic strategies in neurovascular care."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Infectious Disease • Ischemic stroke • Pneumonia • Respiratory Diseases

Efficacy and safety of intra-arterial tirofiban in acute ischemic stroke without large-vessel occlusion. (PubMed, Neuro Endocrinol Lett) - "Intra-arterial tirofiban administration benefits AIS patients without large- or medium-vessel occlusions, improving neurological function, reducing disability, and enhancing functional independence."

Journal • Cardiovascular • Ischemic stroke

Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial. (PubMed, Am J Cardiovasc Drugs) - P2/3 | "Intravenous tirofiban significantly reduced the risk of END compared with aspirin in patients with AIS who were not on prestroke APT. Although this benefit was attenuated in pretreated patients, tirofiban might maintain a consistent efficacy and safety profile irrespective of prior antiplatelet use."

Journal • Cardiovascular • Ischemic stroke

Development and validation of an interpretable machine learning model to predict malignant cerebral edema after endovascular treatment in acute anterior circulation large vessel occlusion stroke. (PubMed, Front Neurol) - "Additional 162 patients from the One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China (OPTIMISTIC) trial were included as an external validation set...The random forest model performed best, achieving an AUC of 0.901 (95% CI: 0.858-0.943) in the training set, 0.849 (95% CI: 0.700-0.970) in the internal validation set, and 0.724 (95% CI: 0.606-0.841) in the external validation set. This study developed and externally validated an interpretable machine learning model to predict the risk of MCE in patients with acute anterior circulation LVO stroke following EVT."

Journal • Cardiovascular • Ischemic stroke

Thrombolysis with Adjunctive Tirofiban in Acute Non-cardioembolic Posterior Circulation Ischemic Stroke: A Propensity Score-Matched Analysis. (PubMed, Neurol Ther) - "In patients with acute non-cardioembolic posterior circulation ischemic stroke treated within 24 h of onset, adjunctive tirofiban following standard intravenous thrombolysis was associated with significantly improved 90-day functional outcomes without a notable increase in major bleeding risk, particularly in patients with lower baseline NIHSS scores."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Tirofiban-induced lingual edema and thrombocytopenia during management of ischemic stroke: a case report. (PubMed, Neurol Sci) - No abstract available

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombocytopenia

STRATEGY: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (clinicaltrials.gov) - P4 | N=970 | Completed | Sponsor: Beijing Tiantan Hospital | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2025

Trial completion • Trial completion date • Trial primary completion date

RESCUE-AS: Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion (clinicaltrials.gov) - P3 | N=564 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

New P3 trial • Atherosclerosis • Cardiovascular • Ischemic stroke

Safety and efficacy of adjunctive Tirofiban and Eptifibatide in acute ischemic stroke: a systematic review and meta-analysis. (PubMed, J Stroke Cerebrovasc Dis) - "Our meta-analysis suggests that while adjunctive tirofiban or eptifibatide with IVT do not yield benefits in terms of reducing mortality or improving functional independence at 90 days in AIS, emerging evidence from RCTs indicates that tirofiban may offer functional benefits, though this remains uncertain. Importantly, adjunctive therapy did not demonstrate a significant increase in bleeding risk in the analyzed studies. . These findings support the need for further large-scale, high-quality randomized controlled trials to explain the role of tirofiban in the management of AIS."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology

High-throughput combinatorial screening of antiplatelet drugs for personalized medicine. (PubMed, Microsyst Nanoeng) - "We demonstrate that the C-chip can effectively identify the optimal combinations of three clinically relevant antiplatelet drugs: Aspirin, Tirofiban, and Ticagrelor. We further applied this platform to identify optimal drug combinations for five healthy volunteers, revealing marked inter-individual variability in antiplatelet drug responses."

Journal • Cardiovascular • Myocardial Infarction

Adjunct tirofiban after intravenous thrombolysis in acute ischemic stroke: a GRADE-guided meta-analysis of randomized trials with trial sequential analysis. (PubMed, J Thromb Thrombolysis) - "Our analysis assessed the efficacy and safety of adjunct tirofiban after IVT versus IVT alone (alteplase or Tenecteplase) in patients with AIS. For safety, no statistically significant differences were observed in any ICH, asymptomatic ICH, systemic bleeding, or 90-day mortality; however, the estimate for sICH was very imprecise and does not exclude a clinically important increase. These results are exploratory and warrant confirmation in larger, multinational RCTs before informing practice."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke